PDT Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

PDT Partners’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41,760	Closed	-$1.12M	–	1221
2022 Q1	$1.12M	Buy	+41,760	New	+$1.4M	0.1%	334
2021 Q4	–	Sell	-6,591	Closed	-$438K	–	1068
2021 Q3	$438K	Buy	+6,591	New	+$470K	0.03%	505
2021 Q2	–	Sell	-5,180	Closed	-$490K	–	1000
2021 Q1	$490K	Buy	+5,180	New	+$616K	0.04%	517
2020 Q2	–	Sell	-11,817	Closed	-$528K	–	876
2020 Q1	$528K	Buy	11,817 +4,100	+53%	+$218K	0.04%	358
2019 Q4	$481K	Buy	+7,717	New	+$367K	0.03%	427

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PDT Partners's TPTX Position: Q2 2022 in Review

PDT Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 41,760 shares — an estimated $1.12M sold.

PDT Partners first reported a position in TPTX in Q4 2019 and held it in 5 quarters. The position peaked at $1.12M in Q1 2022. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

PDT Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 41,760 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.12M.
PDT Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
PDT Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.12M in Q1 2022.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.